What is the R&D strength of Hengrui Pharma?

As one of the most innovative pharmaceutical leading enterprises in China, Hengrui Pharma has overcome difficulties and promoted the high-quality development of the pharmaceutical industry. In the past ten years, it has invested 29.2 billion yuan in research and development, ranking among the best in the national pharmaceutical industry. The company has set up 14 R&D centers in Lianyungang, Shanghai, the United States and Europe, with a global R&D team of more than 5,000 people. High-intensity R&D investment urges the company to continuously enrich and develop its R&D pipeline. In addition to the traditional anti-tumor field, the company is also widely distributed in autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory diseases, blood diseases, nervous system diseases, ophthalmology, nuclear medicine and other fields, forming a competitive R&D pipeline layout.